When professional care is needed, Health AI can connect patients directly to One Medical providers through message, video or in-person
These findings position GLP-1RAs as a potential fourth pillar of kidney-protective therapy in diabetes, alongside renin-angiotensin system inhibitors (RASi), SGLT2i, and finerenone, and suggest a shift toward rapid initiation of combination therapies for maximum kidney protection
Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ
En funcin de la evidencia farmacolgica, de los datos de investigaciones clnicas y de estudios de vida real, los AR-GLP1 pueden considerarse como agentes nefroprotectores para los pacientes con DM2 y ERC, caracterizada por su elevada morbilidad secundaria al compromiso renal y CV.
Some GLP-1 medications are also approved specifically for weight loss in adults with obesity, or who are overweight with related health problems
This is because it has the same ingredient as Wegovy, which is approved for weight management